Search

Author/Creator Tasset, C.

3. FRI0339 LONG-TERM EFFICACY OF THE ORAL SELECTIVE JANUS KINASE 1 INHIBITOR FILGOTINIB IN PSORIATIC ARTHRITIS: WEEK 52 RESPONSE PATTERNS IN INDIVIDUAL PATIENTS FROM AN OPEN-LABEL EXTENSION (OLE) STUDY (EQUATOR2). (2nd June 2020)

Authors:
Gladman, D. D.; Coates, L. C.; Van den Bosch, F.; Helliwell, P.; Tasset, C.; Meuleners, L.; Gilles, L.; Gheyle, L.; Trivedi, M.; Alani, M.; Besuyen, R.; Mease, P. J.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
763
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. FRI0343 EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR). (2nd June 2020)

Authors:
Helliwell, P.; Van den Bosch, F.; Coates, L. C.; Gladman, D. D.; Tasset, C.; Meuleners, L.; Gilles, L.; Gheyle, L.; Trivedi, M.; Alani, M.; Besuyen, R.; Mease, P. J.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
765
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. FRI0344 THE LONG-TERM EFFECT OF TREATING PSORIATIC ARTHRITIS WITH THE JANUS KINASE 1-SELECTIVE INHIBITOR FILGOTINIB ON LIPID PROFILES: AN ANALYSIS OF THE EQUATOR AND EQUATOR2 TRIALS. (2nd June 2020)

Authors:
Husni, M. E.; Gladman, D. D.; Helliwell, P.; Van den Bosch, F.; Tasset, C.; Meuleners, L.; Gilles, L.; Gheyle, L.; Trivedi, M.; Alani, M.; Besuyen, R.; Mease, P. J.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
766
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. OP0224 Filgotinib (GLPG0634), An Oral Jak1 Selective Inhibitor Is Effective in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: Results from A 24-Week Phase 2B Dose Ranging Study. (15th July 2016)

Authors:
Westhovens, R.; Alten, R.; Pavlova, D.; Enriquez Sosa, F.E.; Mazur, M.; Greenwald, M.; Van der, Aa A.; Vanhoutte, F.; Tasset, C.; Harrison, P.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 75(2016)Supplement 2
Page Start:
142
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. SAT0158 EFFICACY AND SAFETY OF FILGOTINIB IN METHOTREXATE-NAÏVE PATIENTS WITH RHEUMATOID ARTHRITIS: FINCH 3 52-WEEK RESULTS. (2nd June 2020)

Authors:
Westhovens, R.; Rigby, W.; Van der Heijde, D.; Ching, D.; Stohl, W.; Kay, J.; Chopra, A.; Bartok, B.; Matzkies, F.; Yin, Z.; Guo, Y.; Tasset, C.; Sundy, J.; Jahreis, A.; Mozaffarian, N.; Messina, O.; Landewé, R. B. M.; Atsumi, T.; Burmester, G. R.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
1019
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. SAT0231 Effects of the jak1-selective inhibitor filgotinib on gene expression profile in blood of patients with active rheumatoid arthritis. (12th June 2018)

Authors:
Taylor, P. C.; Tarrant, J.; Zhao, L.; Gindin, Y.; Mirza, A.; Harrison, P.; Tasset, C.; Galien, R.; Van der Aa, A.; Downie, B.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 77(2018)Supplement 2
Page Start:
976
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. THU0167 The Effect of Filgotinib (GLPG0634), An Oral Jak1 Selective Inhibitor on Patient-Reported Outcomes: Results from Two 24-Week Phase 2b Dose Ranging Studies. (15th July 2016)

Authors:
Genovese, M.; Westhovens, R.; Kavanaugh, A.; Meuleners, L.; Van der, Aa A.; Harrison, P.; Tasset, C.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 75(2016)Supplement 2
Page Start:
244
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗